BRPI9815772A - emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn - Google Patents

emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn

Info

Publication number
BRPI9815772A
BRPI9815772A BRPI9815772A BRPI9815772A BRPI9815772A BR PI9815772 A BRPI9815772 A BR PI9815772A BR PI9815772 A BRPI9815772 A BR PI9815772A BR PI9815772 A BRPI9815772 A BR PI9815772A BR PI9815772 A BRPI9815772 A BR PI9815772A
Authority
BR
Brazil
Prior art keywords
neurodermatitis
crohn
psoriasis
treatment
psoriatic arthritis
Prior art date
Application number
BRPI9815772A
Other languages
English (en)
Inventor
Rajendra K Joshi
Hans-Peter Strebel
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of BRPI9815772A publication Critical patent/BRPI9815772A/pt
Publication of BRPI9815772B1 publication Critical patent/BRPI9815772B1/pt
Publication of BRPI9815772B8 publication Critical patent/BRPI9815772B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

patente de invenção: <b>"emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn"<d>. emprego de um ou vários hidrogeno fumaratos de alquila da fórmula geral: onde r é uma c~ 1-5~ alquila, opcionalmente em mistura com fumarato de dialquila da fórmula: e opcionalmente excipientes e veículos farmacêuticos costumeiros para preparação de uma composição farmacêutica na forma de microcomprimidos ou micropéletes para tratamento de psoríase, artrite psoriática, neurodermatite e enterite regional de crohn.
BRPI9815772 1998-03-31 1998-12-08 emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn BRPI9815772B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814358A DE19814358C2 (de) 1998-03-31 1998-03-31 Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
PCT/EP1998/007956 WO1999049858A1 (de) 1998-03-31 1998-12-08 Verwendung von alkylhydrogenfumaraten zur behandlung von psoriasis, psoriatischer arthritis, neurodermitis und enteritis regionalis crohn

Publications (3)

Publication Number Publication Date
BRPI9815772A true BRPI9815772A (pt) 2000-11-21
BRPI9815772B1 BRPI9815772B1 (pt) 2016-02-10
BRPI9815772B8 BRPI9815772B8 (pt) 2021-07-06

Family

ID=7863089

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9815772 BRPI9815772B8 (pt) 1998-03-31 1998-12-08 emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn

Country Status (25)

Country Link
US (1) US6277882B1 (pt)
EP (1) EP1059920B1 (pt)
JP (1) JP3527890B2 (pt)
CN (1) CN1150898C (pt)
AT (1) ATE219936T1 (pt)
AU (1) AU745281B2 (pt)
BG (1) BG64744B1 (pt)
BR (1) BRPI9815772B8 (pt)
CA (1) CA2283915C (pt)
CZ (1) CZ291788B6 (pt)
DE (2) DE19814358C2 (pt)
DK (1) DK1059920T3 (pt)
EE (1) EE04702B1 (pt)
ES (1) ES2179551T3 (pt)
HU (1) HU228848B1 (pt)
IL (1) IL136835A (pt)
NO (1) NO327750B1 (pt)
NZ (1) NZ505341A (pt)
PL (1) PL191803B1 (pt)
PT (1) PT1059920E (pt)
RS (1) RS49658B (pt)
RU (1) RU2197233C2 (pt)
SK (1) SK285187B6 (pt)
TR (1) TR200001829T2 (pt)
WO (1) WO1999049858A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
CA2776023A1 (en) * 2001-01-12 2002-07-18 Fumapharm Ag Fumaric acid amides
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
DK1663197T3 (da) * 2003-09-09 2008-01-07 Fumapharm Ag Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
SI1799196T1 (sl) 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
WO2007006308A1 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP2653873B8 (en) 2007-02-08 2022-08-24 Biogen MA Inc. Compositions and uses for treating Multiple Sclerosis
HUE032251T2 (en) * 2007-02-08 2017-09-28 Biogen Ma Inc Neuroprotection in demyelinating diseases
MX2011001341A (es) 2008-08-19 2011-03-29 Xenoport Inc Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso.
EP2564839B1 (en) 2009-01-09 2016-05-11 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
PE20141639A1 (es) 2011-06-08 2014-11-08 Biogen Idec Inc Proceso para preparar fumarato de dimetilo de alta pureza y cristalino
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CA2862885C (en) 2012-02-07 2020-06-02 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
NZ629728A (en) 2012-02-07 2016-07-29 Xenoport Inc Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
KR101449114B1 (ko) * 2012-08-21 2014-10-13 바이오스펙트럼 주식회사 푸마르산을 유효성분으로 포함하는 항염 조성물
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
MX386935B (es) 2013-03-14 2025-03-04 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
AU2014314231A1 (en) 2013-08-26 2016-03-03 Fwp Ip Aps Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
US20150079180A1 (en) 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
JP6337135B2 (ja) 2014-02-24 2018-06-06 アルカーメス ファーマ アイルランド リミテッド フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
IL252962B (en) 2015-02-08 2022-07-01 Alkermes Pharma Ireland Ltd Monomethylfumarate prodrug compositions
EP3273951B1 (en) 2015-03-27 2020-07-29 Symbionyx Pharmaceuticals Inc. Compositions and methods for treating psoriasis
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
CN105496804A (zh) * 2015-12-25 2016-04-20 知识产权全资有限公司 用于处理头发以及治疗头部牛皮藓的配方及其试剂盒和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE3127432A1 (de) * 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
US5214196A (en) * 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
DE8714143U1 (de) * 1987-10-23 1988-03-24 Werler Kunststoffwerke GmbH & Co, 4760 Werl Sitz- und/oder Liegemöbel
DE3834794A1 (de) * 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
AU1271592A (en) * 1991-01-18 1992-08-27 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
US5407772A (en) * 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
US5972363A (en) * 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition

Also Published As

Publication number Publication date
HK1035134A1 (en) 2001-11-16
NZ505341A (en) 2002-04-26
RS49658B (sr) 2007-09-21
CA2283915A1 (en) 1999-09-30
NO20002872L (no) 2000-06-06
BG64744B1 (bg) 2006-02-28
CN1284870A (zh) 2001-02-21
CZ20003086A3 (cs) 2000-11-15
AU745281B2 (en) 2002-03-21
HU228848B1 (en) 2013-06-28
SK7922000A3 (en) 2001-01-18
NO327750B1 (no) 2009-09-14
RU2197233C2 (ru) 2003-01-27
DE59804704D1 (de) 2002-08-08
YU32000A (sh) 2002-03-18
EE200000440A (et) 2001-12-17
HUP0103234A3 (en) 2003-11-28
JP2002509883A (ja) 2002-04-02
CN1150898C (zh) 2004-05-26
PT1059920E (pt) 2002-11-29
EP1059920A1 (de) 2000-12-20
BRPI9815772B1 (pt) 2016-02-10
PL341240A1 (en) 2001-03-26
BG104566A (en) 2001-01-31
CA2283915C (en) 2002-12-03
US6277882B1 (en) 2001-08-21
IL136835A (en) 2005-05-17
AU2159399A (en) 1999-10-18
HUP0103234A2 (hu) 2002-01-28
BRPI9815772B8 (pt) 2021-07-06
NO20002872D0 (no) 2000-06-06
EP1059920B1 (de) 2002-07-03
JP3527890B2 (ja) 2004-05-17
WO1999049858A1 (de) 1999-10-07
TR200001829T2 (tr) 2000-11-21
SK285187B6 (sk) 2006-08-03
DE19814358A1 (de) 1999-10-07
IL136835A0 (en) 2001-06-14
CZ291788B6 (cs) 2003-05-14
ES2179551T3 (es) 2003-01-16
PL191803B1 (pl) 2006-07-31
ATE219936T1 (de) 2002-07-15
DE19814358C2 (de) 2002-01-17
DK1059920T3 (da) 2002-10-14
EE04702B1 (et) 2006-10-16

Similar Documents

Publication Publication Date Title
BRPI9815772B8 (pt) emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn
US5091171B1 (en) Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use
BR9910267A (pt) Microcomprimidos de ácido fumárico
BRPI9909282A (pt) compostos de éter aminociclohexílicos e usos dos mesmos.
BR9811923A (pt) Compostos possuindo atividade neuronal
MY103352A (en) Piperazinyl-heterocyclic compounds
GR3018541T3 (en) Condensed heterocyclic compounds and their use in therapy.
BRPI0413582A (pt) compostos, composições e métodos para inibir a atividade de proteasome
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
BRPI0411295A (pt) compostos e seu uso na terapia
PT866791E (pt) Diaminopirimidinas formulacoes farmaceuticas que as contem e sua utilizacao antibacteriana
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
BR9908443A (pt) Linhagens de células de medula espinhal humana e métodos para uso das mesmas
BR9810996A (pt) Composição farmacêutica
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
BR9813897A (pt) Derivados de bifenila como farmacêuticos
HUP0000569A3 (en) Use of equilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
BR9906350A (pt) Composição contendo cetanserina e l-carnitina ou uma alcanoil l-carnitina para o tratamento de crps
BR9910401A (pt) Nova formulação contendo paroxetina
PT795008E (pt) Linhas de celulas de condrocitos hipertroficos humanos
BR0108823A (pt) Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva
BR0005161A (pt) Bebedouro para água